Tepotinib tablets 225mg/tablet, 60 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Interstitial lung disease (ILD)/pneumonia: Immediate discontinuation of LuciTepo in patients with suspected ILD/pneumonia. Permanently discontinue LuciTepo in patients diagnosed with any severity of ILD/pneumonia.
• Hepatotoxicity: Monitor liver function tests. Depending on the severity, discontinue, reduce the dose, or permanently discontinue LuciTepo.
• Pancreatic toxicity: monitor for amylase and lipase. Depending on the severity, discontinue, reduce the dose, or permanently discontinue LuciTepo.
• Embryo-fetal toxicity: LuciTepo can cause fetal harm. Potential risks to the fetus and the use of effective contraception are recommended.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) are edema, nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea, decreased appetite, and rash. The most common grade 3 to 4 laboratory abnormalities (≥ 2%) are lymphopenia, decreased albumin, decreased sodium, increased gamma-glutamyltransferase, increased amylase, increased lipase, increased ALT, increased AST, and decreased hemoglobin.